✦ LIBER ✦

Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma

✍ Scribed by Leonard, J. P.; Link, B. K.; Emmanouilides, C.; Gregory, S. A.; Weisdorf, D.; Andrey, J.; Hainsworth, J.; Sparano, J. A.; Tsai, D. E.; Horning, S.; Krieg, A. M.; Weiner, G. J.

Book ID: 127302012
Publisher: American Association for Cancer Research
Year: 2007
Tongue: English
Weight: 196 KB
Volume: 13
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.ccr-07-0815

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of a Toll-like receptor 9

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

✍ Youn H. Kim; Michael Girardi; Madeleine Duvic; Timothy Kuzel; Brian K. Link; Lau 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 491 KB

Rituximab as first-line and maintenance

Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial

✍ John D Hainsworth 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Phase Ib trial of the Toll-like receptor

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

✍ Machiels, Jean-Pascal; Kaminsky, Marie-Christine; Keller, Ulrich; Brümmendorf, T 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 333 KB